FDA Panel Casts SSRIs During Pregnancy as Risky—Many Experts Disagree

Key Points

• SSRIs are deemed risky during pregnancy, according to an FDA panel, yet many specialists argue against this view.
• The panel's conclusions may influence treatment options for pregnant individuals, contributing to an ongoing debate.
• Expert disagreement on antidepressant safety in pregnancy raises questions about patient care and medication guidelines.
• The FDA's stance on SSRIs could lead to more scrutiny on prescribing practices and further investigations.